Danaher outdoes low fourth-quarter revenue expectations, forecasts slow 2024

Dana­her’s rev­enue for the last three months of 2023 dropped by 11.5% com­pared to the same time in 2022, yet this was a bet­ter out­come than ex­pect­ed, with rev­enue pri­mar­i­ly gen­er­at­ed from its mol­e­c­u­lar di­ag­nos­tics sub­sidiary Cepheid, the com­pa­ny said Tues­day morn­ing.

The con­glom­er­ate al­so not­ed that its core 2024 rev­enue is pre­dict­ed to de­cline to “high-sin­gle dig­its” for the first quar­ter of 2024 and “low-sin­gle dig­its” for the whole year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.